Rare Diseases
Conference Coverage
Answers sought for mental health challenges in pediatric rheumatology patients
One study found a tremendous increase in screening by automating the process while another found remote delivery of a 6-week cognitive-behavioral...
Latest News
Cancer, heart disease vaccines may be ready by 2030, Moderna says
The announcement is yet another sign of what many are calling “the golden age” of vaccine development.
Conference Coverage
Childhood lupus severity linked to social determinants of health
Social determinants of health were linked to lupus disease severity in children, but it will take more than awareness among doctors to address the...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Latest News
Phase 3 prurigo nodularis trial shows positive results for nemolizumab
“The use of topical steroids was not allowed in this trial,” Dr. Shawn G. Kwatra said.
News
FDA OKs first drug for Rett syndrome
The drug is designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.
Latest News
Maternal infection in pregnancy ups risk for childhood leukemia?
Maternal infections during pregnancy may be associated with chromosomal and immunologic alterations in the fetus, the authors of the study...
From the Journals
Antibiotics and SJS/TEN: Study provides global prevalence
Sulfonamides responsible for the highest proportion of antibiotic-triggered Stevens-Johnson syndrome and toxic epidermal necrolysis.
Opinion
A White male presented with a 1½-year history of a progressive hypoesthetic annular, hyperpigmented plaque on the upper arm
A patient presents with a subtle, solitary 4-cm annular skin-colored thin plaque on his left posterior upper arm.
Feature
More data back Guillain-Barré risk with Janssen COVID shot
Observed GBS cases after the Janssen shot were 2 to 3 times greater than expected, based on background rates within 21 and 42 days of vaccination...
Latest News
Topical gene therapy heals dystrophic epidermolysis bullosa wounds
“The results prove that B-VEC, the first topical in vivo gene therapy to reach late-stage development, can heal DEB,” one of the investigators...